Pfizer Secures Major Financing for Obesity Drug and New Health Tech Advances
Recent medical and technological innovations highlight new tools for REM sleep enhancement, insights into social jetlag in children, Pfizer's $1.5 billion obesity drug financing, and Google's advanced genomic models.

Ultrasound Device Enhances REM Sleep and Brain Resilience
Researchers at the University of Texas at Austin have developed a wearable skin patch that utilizes ultrasound waves to stimulate brain activity and improve sleep quality. Published in the journal Nature Communications, initial findings demonstrate that users equipped with the device entered REM sleep 43 minutes earlier and remained in this critical stage 16 minutes longer than control subjects receiving a simulated treatment. REM sleep is essential for memory consolidation, emotional regulation, and stress resilience.
The adhesive patch continuously monitors brain responses to gentle acoustic waves, allowing it to adapt its stimulation dynamically. Tested on individuals both with and without sleep disorders, the device successfully advanced and extended REM sleep across all participants. Furthermore, patients exhibited improvements in heart rate variability, a key indicator of cardiovascular health and stress management. Researchers are now investigating whether the technology can assist individuals suffering from post-traumatic stress disorder, who frequently experience severe sleep disturbances.
Study Links Social Jetlag to Weight Gain in Children
Researchers at Ariel University have examined the phenomenon of "social jetlag"—the discrepancy between an individual's biological clock and societal scheduling demands—among children aged 4 to 10. Contrary to the common perception that young children naturally wake up early regardless of the day of the week, the study revealed significant social jetlag in this age group, which correlated with higher Body Mass Index measurements.
Pfizer Secures External Financing for Obesity Drug Development
Pharmaceutical giant Pfizer has entered into an unconventional financing agreement with Blackstone Life Sciences, under which the firm will fund up to $1.5 billion in development costs for Pfizer's monthly injectable obesity treatment. In exchange, Blackstone will receive a percentage of product revenues if the medication successfully reaches the market. With substantial long-term debt stemming from the acquisition of Seagen and an upcoming patent cliff, Pfizer is leveraging external capital to advance its leading obesity candidate while preserving financial flexibility.
Pfizer plans to conduct approximately ten clinical trials simultaneously to evaluate the drug's efficacy across various indications, ranging from standalone obesity management to associated conditions such as osteoarthritis and obstructive sleep apnea. This development follows previous setbacks in Pfizer's metabolic portfolio, leaving the Blackstone-backed asset as its primary advanced candidate in the obesity sector.
Google DeepMind Unveils AlphaGenome2 for Genomic Analysis
Google's DeepMind has introduced AlphaGenome2, an advanced computational model designed to predict the cellular impact of genomic variations. Building on its predecessor and the AlphaGenome Atlas, the new architecture focuses specifically on how genetic mutations influence distinct cell types, where gene expression patterns vary. Alongside the genomic tool, Google announced Gemini For Healthcare to integrate medical, logistical, and financial data for healthcare systems, as well as an artificial intelligence conversational platform developed in collaboration with Clalit Health Services and Google.org to assist patients using specialized phones or those facing digital navigation barriers.





